Drug news

Mallinckrodt terminates co-promotion of Sumavel Dose Pro with Zogenix

Read time: 1 mins

Last updated:10th Jan 2014

Published:10th Jan 2014

Source: Pharmawand

MallinckrodtL announced a mutually-agreed upon end of the company�s co-promotion agreement with Zogenix . The co-promotion agreement covered Sumavel DosePro (sumatriptan injection), a prescription medicine given with a needle-free delivery system to treat adults who have been diagnosed with acute Migraine or cluster Headaches. Mallinckrodt�s promotion of Sumavel DosePro will end January 31, 2014.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

European Commission approval for Kalydeco to treat infants with cystic fibrosis ages 1 month and older.- Vertex.

Vertex Pharmaceuticals announced that the European Commission has granted approval for the label expansion of Kayydeco (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.

1 mins

Drug news

Novavax is prepared to deliver protein-based non-mRNA JN.1 COVID-19 vaccine in line with WHO recommendation this fall.

Novavax is Prepared to Deliver Protein-based Non-mRNA JN.1 COVID-19 Vaccine in Line with WHO Recommendation this Fall

1 min

Drug news

CHMP positive for Jeraygo (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.- Idorsia Ltd.

Idorsia Ltd announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), adopted a positive opinion for the use of Jeraygo (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.

1 min

See all news